Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban
- 12 February 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 58 (3) , 474-476
- https://doi.org/10.1212/wnl.58.3.474
Abstract
In an open pilot study, the authors tested whether the nonpeptide glycoprotein (GP) IIb/IIIa antagonist tirofiban, a highly effective and selective blocker of platelet aggregation, prevents the transition of ischemic brain tissue into the infarct proper as defined by MRI (perfusion-weighted/T2-weighted) in patients with acute ischemic stroke. The infarct volume (T2 lesion after 1 week) was smaller in treated patients (n = 10) compared with matched control subjects (n = 10; p = 0.029) with similar initial perfusion deficit (TTP-maps). The authors conclude that GP IIb/IIIa antagonists have therapeutic potential in acute stroke therapy.Keywords
This publication has 6 references indexed in Scilit:
- Integrin α IIb β 3 Inhibitor Preserves Microvascular Patency in Experimental Acute Focal Cerebral IschemiaStroke, 2000
- Abciximab in Acute Ischemic StrokeStroke, 2000
- Diffusion and perfusion magnetic resonance imaging for the evaluation of acute stroke: potential use in guiding thrombolytic therapyCurrent Opinion in Neurology, 2000
- Diffusion- and Perfusion-Weighted MRIStroke, 1999
- Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.Journal of Clinical Investigation, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998